Immunotherapy: SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIAL

Detalles Bibliográficos
Autores principales: Papadopoulou, A., Karavalakis, G., Papadopoulou, E., Xochelli, A., Bousiou, Z., Vogiatzoglou, A., Papayanni, P.G., Georgakopoulou, A., Giannaki, M., Stavridou, F., Vallianou, I., Kammenou, M., Varsamoudi, E., Papadimitriou, V., Giannaki, C., Sileli, M., Stergiouda, Z., Stefanou, G., Kourlaba, G., Triantafyllidou, M., Siotou, E., Karaglani, A., Zotou, E., Chatzika, G., Boukla, A., Apostolou, D., Pitsiou, G., Morfesis, P., Bartzoudis, D., Imprialos, K., Karampatakis, T., Kapravelos, N., Bitzani, M., Theodorakopoulou, M., Serasli, E., Sakellari, I., Fylaktou, A., Tryfon, S., Anagnostopoulos, A., Yannaki, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society for Cell & Gene Therapy. Published by Elsevier Inc. 2022
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035757/
http://dx.doi.org/10.1016/S1465-3249(22)00147-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035757/
http://dx.doi.org/10.1016/S1465-3249(22)00147-5

Ejemplares similares